METHODS FOR THE PREVENTION AND TREATMENT OF BURN INJURIES AND SECONDARY COMPLICATIONS

• US 20100331265A1
• Filed: 03/19/2010
• Published: 12/30/2010
• Est. Priority Date: 03/20/2009
• Status: Abandoned Application

• Current Assignee: The General Hospital Corporation (Mass General Brigham, Inc.)
• Original Assignee: The General Hospital Corporation (Mass General Brigham, Inc.)
• Inventors: Tzika, A. Aria, Martyn, Jeevendra A., Rahme, Laurence, Yu, Yong-Ming, Tompkins, Ronald G.
• Application Number:
  US12/727,647
• Publication Number:
  US 20100331265A1
• Time in Patent Office: Days
• US Class Current: 514/21.9
• CPC Class Codes: A61K 38/07 Tetrapeptides
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/02 Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/16 Emollients or protectives, e.g. against radiation
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The disclosure relates to methods for treating a subject suffering from a burn injury or associated complications by administering to the subject an effective amount of an aromatic-cationic peptide. For example, a burn injury may be associated with distant pathophysiological effects, such as hypermetabolism, skeletal muscle dysfunction, and organ damage. The disclosure also relates to methods for protecting a subject from a burn injury by administering an effective amount of an aromatic-cationic peptide to a subject at risk of a burn injury.

Claims

1. A method for treating a subject suffering from a burn injury or a systemic injury or condition secondary to a burn, the method comprising administering to the subject in need thereof an effective amount of a peptide having the formula D-Arg-2′

6′

-dimethyltyrosine-Lys-Phe-NH₂.

2. The method of claim 1, wherein the systemic injury is organ dysfunction or failure.

3. The method of claim 2, wherein the organ dysfunction or failure affects one or more of the lung, liver, kidneys, or bowel.

4. The method of claim 2, wherein the peptide is administered following a burn injury but prior to the onset of symptoms of organ dysfunction or failure.

5. The method of claim 2, wherein the peptide is administered following the onset of symptoms of organ dysfunction or failure.

6. The method of claim 1, wherein the systemic injury is hypermetabolism.

9. The method of claim 1, wherein the systemic injury is skeletal muscle dysfunction.

13. The method of claim 1, wherein the subject is a human.

14. The method of claim 1, wherein the peptide is administered intravenously, orally, subcutaneously, transdermally, intraperitoneally, or topically.

7. The method of claim 7, wherein the peptide is administered following a burn injury but prior to the onset of symptoms of hypermetabolism.

8. The method of claim 7, wherein the peptide is administered following the onset of symptoms hypermetabolism.

10. The method of claim 10, wherein the skeletal muscle dysfunction is skeletal muscle wasting or cachexia.

11. The method of claim 10, wherein the peptide is administered following a burn injury but prior to the onset of symptoms of skeletal muscle dysfunction.

12. The method of claim 10, wherein the peptide is administered following the onset of symptoms skeletal muscle dysfunction.

15. A method for protecting the subject against a burn injury, the method comprising administering to the subject in need thereof an effective amount of a peptide having the formula D-Arg-2′

6′

-dimethyltyrosine-Lys-Phe-NH₂ prior to a burn injury.

16. The method of claim 15, wherein the peptide is administered topically.

17. The method of claim 21, wherein the burn injury is a sunburn or radiation burn.

18. A method for treating a disease or condition characterized by a reduced ATP synthesis rate, the method comprising administering to a mammal in need thereof an effective amount of a peptide having the formula D-Arg-2′

6′

-dimethyltyrosine-Lys-Phe-NH₂ in order to increase the ATP synthesis rate in the subject.

19. The method of claim 18, wherein the disease or condition is a burn injury.

20. The method of claim 18, wherein increasing the ATP synthesis rate is by increasing the expression or activity of the peroxisome proliferator activated receptor-gamma coactivator-1β

(PGC-1β

) protein.